# A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

> **NCT06619561** · PHASE2 · RECRUITING · sponsor: **Deciphera Pharmaceuticals, LLC** · enrollment: 48 (estimated)

## Conditions studied

- Chronic Graft-Versus-Host Disease (cGVHD)

## Interventions

- **DRUG:** Vimseltinib

## Key facts

- **NCT ID:** NCT06619561
- **Lead sponsor:** Deciphera Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-21
- **Primary completion:** 2029-10
- **Final completion:** 2029-10
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06619561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06619561, "A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06619561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*